Literature DB >> 2032519

Animal models of fulminant hepatic failure.

J Terblanche1, R Hickman.   

Abstract

The six requirements for a satisfactory animal model of fulminant hepatic failure are reversibility, reproducibility, death from liver failure, a therapeutic window, a large animal model, and minimal hazard to personnel. Different models may be required to evaluate the various types of liver failure seen in man. The available models include surgical anheptic and devascularization procedures, as well as hepatotoxic drug administration using agents such as carbon tetrachloride, acetaminophen, or galactosamine. Currently combined surgical and drug models appear to provide the best model but the search for the ideal models continues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032519     DOI: 10.1007/bf01311235

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Effect of insulin and glucagon on fulminant murine hepatitis.

Authors:  M Farivar; J R Wands; K J Isselbacher; N L Bucher
Journal:  N Engl J Med       Date:  1976-12-30       Impact factor: 91.245

2.  Total hepatectomy as temporary approach to acute hepatic or primary graft failure.

Authors:  B Ringe; R Pichlmayr; N Lübbe; A Bornscheuer; E Kuse
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

3.  The protective effects of prostaglandin E1 in an experimental massive hepatic cell necrosis model.

Authors:  Y Mizoguchi; H Tsutsui; K Miyajima; Y Sakagami; S Seki; K Kobayashi; S Yamamoto; S Morisawa
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

4.  The effect of hepatectomy on body water distribution.

Authors:  J B Freeman; H M Shizgal; M Slapack; J R Gutelius
Journal:  J Surg Res       Date:  1973-01       Impact factor: 2.192

5.  Transplantation of the liver in adults and children with fulminant hepatic failure.

Authors:  C Vickers; J Neuberger; J Buckels; P McMaster; E Elias
Journal:  J Hepatol       Date:  1988-10       Impact factor: 25.083

6.  Acute hepatic ischaemia in the pig- the changes in plasma hormones, amino acids and brain biochemistry.

Authors:  T Wustrow; R van Hoorn-Hickman; W A van Hoorn; A I Vinik; M Fischer; J Terblanche
Journal:  Hepatogastroenterology       Date:  1981-06

7.  Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: reversal by a benzodiazepine antagonist.

Authors:  M Baraldi; M L Zeneroli; E Ventura; A Penne; G Pinelli; P Ricci; M Santi
Journal:  Clin Sci (Lond)       Date:  1984-08       Impact factor: 6.124

8.  Hepatitis type A, B, and non-A non-B in fulminant hepatitis.

Authors:  L R Mathiesen; P Skinoj; J O Nielsen; R H Purcell; D Wong; L Ranek
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

9.  Protection of thermochemotherapeutic-induced lethal acute hepatic necrosis in the rat by 16,16-dimethyl prostaglandin E2.

Authors:  M Miyazaki; L Makowka; R E Falk; J A Falk; M McDonell; D Venturi
Journal:  J Surg Res       Date:  1983-05       Impact factor: 2.192

10.  The effect of prostaglandins, branched-chain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure.

Authors:  M H Alp; R Hickman
Journal:  J Hepatol       Date:  1987-02       Impact factor: 25.083

View more
  31 in total

Review 1.  Animal models of acute hepatic failure.

Authors:  T M Rahman; H J Hodgson
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  A Macaca mulatta model of fulminant hepatic failure.

Authors:  Ping Zhou; Jie Xia; Gang Guo; Zi-Xing Huang; Qiang Lu; Li Li; Hong-Xia Li; Yu-Jun Shi; Hong Bu
Journal:  World J Gastroenterol       Date:  2012-02-07       Impact factor: 5.742

3.  Hybrid bioartificial liver support in cynomolgus monkeys with D-galactosamine-induced acute liver failure.

Authors:  Zhi Zhang; Yi-Chao Zhao; Yuan Cheng; Guo-Deng Jian; Ming-Xin Pan; Yi Gao
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

4.  Protective effect of Salvia miltiorrhiza and Carthamus tinctorius extract against lipopolysaccharide-induced liver injury.

Authors:  Li-Na Gao; Kuo Yan; Yuan-Lu Cui; Guan-Wei Fan; Yue-Fei Wang
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

Review 5.  Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease.

Authors:  Ira J Fox; George Q Daley; Steven A Goldman; Johnny Huard; Timothy J Kamp; Massimo Trucco
Journal:  Science       Date:  2014-08-22       Impact factor: 47.728

6.  Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube.

Authors:  Dmitry Frank; Shiri Savir; Benjamin F Gruenbaum; Israel Melamed; Julia Grinshpun; Ruslan Kuts; Boris Knyazer; Alexander Zlotnik; Max Vinokur; Matthew Boyko
Journal:  J Vis Exp       Date:  2020-04-28       Impact factor: 1.355

7.  An experimental animal model of fulminant hepatic failure in pigs.

Authors:  Kuhn Uk Lee; Long-xian Zheng; Yong Beom Cho; Ki-Ho Kim; Jongwon Ha; Kyung-Suk Suh; Sung Eun Jung
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

8.  A fulminant hepatic failure model in the rat: involvement of interleukin-1beta and tumor necrosis factor-alpha.

Authors:  M Shito; U J Balis; R G Tompkins; M L Yarmush; M Toner
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

9.  Development of an invasively monitored porcine model of acetaminophen-induced acute liver failure.

Authors:  Philip N Newsome; Neil C Henderson; Leonard J Nelson; Costas Dabos; Celine Filippi; Chris Bellamy; Forbes Howie; Richard E Clutton; Tim King; Alistair Lee; Peter C Hayes; John N Plevris
Journal:  BMC Gastroenterol       Date:  2010-03-30       Impact factor: 3.067

Review 10.  An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure.

Authors:  María-Jesús Tuñón; Marcelino Alvarez; Jesús-M Culebras; Javier González-Gallego
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.